Literature DB >> 2549332

A proposed mechanism of the mitogenic action of fluoride on bone cells: inhibition of the activity of an osteoblastic acid phosphatase.

K H Lau1, J R Farley, T K Freeman, D J Baylink.   

Abstract

Fluoride (F) is a potent inhibitor of osteoblastic acid phosphatase activity with an apparent Ki value (10 to 100 mumol/L) that corresponds to F concentrations that increase bone cell proliferation and bone formation in vivo and in vitro. This high sensitivity of acid phosphatase to F inhibition appeared to be specific for skeletal tissues. Mitogenic concentrations of F did not increase cellular cAMP levels but significantly stimulated net protein phosphorylation in intact calvarial cells and in isolated calvarial membranes. These concentrations of F also stimulated net membrane-mediated phosphorylation of angiotensin II (which contains tyrosyl but no seryl or threonyl residues), suggesting that some of the F-stimulated protein phosphorylations could occur on tyrosyl residues. F had no apparent effect on thiophosphorylation of membrane proteins, suggesting that the F-stimulated net protein phosphorylation in bone cells was probably not mediated via activation of protein kinases. Orthovanadate or molybdate at concentrations that inhibit bone acid phosphatase activity also stimulated bone cell proliferation, supporting the idea that inhibition of bone acid phosphatase would lead to stimulation of bone cell proliferation. Mitogenic concentrations of F potentiated the mitogenic activities of insulin, EGF, and IGF-1 (ie, growth factors the receptors of which are tyrosyl kinases) to a greater extent than they potentiated the action of basic FGF (a growth factor that does not appear to stimulate tyrosyl protein phosphorylation). Based on these findings, a model is proposed for the biochemical mechanism of the osteogenic action of F in which F stimulates bone cell proliferation by a direct inhibition of an osteoblastic acid phosphatase/phosphotyrosyl protein phosphatase activity, which in turn increases overall cellular tyrosyl phosphorylation, resulting in a subsequent stimulation of bone cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549332     DOI: 10.1016/0026-0495(89)90232-1

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  18 in total

Review 1.  Growth regulatory factors and bone.

Authors:  G R Mundy; D Chen; M Zhao; S Dallas; C Xu; S Harris
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  NaF induces early differentiation of murine bone marrow cells along the granulocytic pathway but not the monocytic or preosteoclastic pathway in vitro.

Authors:  Akira Oguro; Tomoyuki Kawase; Michiaki Orikasa
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 May-Jun       Impact factor: 2.416

3.  Regulation of Protein Activity and Cellular Functions Mediated by Molecularly Evolved Nucleic Acids.

Authors:  Jie Tan; Mengmeng Zhao; Jie Wang; Zhihao Li; Ling Liang; Liqin Zhang; Quan Yuan; Weihong Tan
Journal:  Angew Chem Int Ed Engl       Date:  2019-01-14       Impact factor: 15.336

Review 4.  Visions for the future in osteoporosis research.

Authors:  G R Mundy
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

5.  Pharmacokinetic profile of a new fluoride preparation: sustained-release monofluorophosphate.

Authors:  H Resch; C Libanati; J Talbot; M Tabuenca; S Farley; P Bettica; W Tritthart; D Baylink
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333

6.  Measurement of total and diffusible serum fluoride.

Authors:  A Rigalli; R Alloatti; R C Puche
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

Review 7.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

8.  Aluminum stimulates the proliferation and differentiation of osteoblasts in vitro by a mechanism that is different from fluoride.

Authors:  K H Lau; A Yoo; S P Wang
Journal:  Mol Cell Biochem       Date:  1991-07-10       Impact factor: 3.396

Review 9.  Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.

Authors:  T M Murray; L G Ste-Marie
Journal:  CMAJ       Date:  1996-10-01       Impact factor: 8.262

Review 10.  The effect of the microscopic and nanoscale structure on bone fragility.

Authors:  M E Ruppel; L M Miller; D B Burr
Journal:  Osteoporos Int       Date:  2008-03-04       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.